Reagents in a bottle

A reaction only changes drug discovery if a medicinal chemist can run it on a Tuesday afternoon with something off the shelf. This is the story of the lab’s reagents that made that jump, from zinc sulfinates — now a 40-member Diversinates toolkit — to sulfonyl hydrazides you can order from a catalogue.

8 chapters ~23 min read 13 key papers
Graphical abstract: a heterocycle plus a metal sulfinate and an oxidant gives the alkylated heterocycle, labelled more than 50 patents, over a background of drug-like structures bearing CF3, CF2H and other groups.
Graphical abstract, Smith, Dixon, deGruyter & Baran, “Alkyl Sulfinates: Radical Precursors Enabling Drug Discovery,” J. Med. Chem. 2019.
Milestones

Timeline

  1. 2011

    Innate CF₃

    A benchtop trifluoromethyl radical source for heterocycles.

    See the paper →
  2. 2012

    DFMS

    Zn(SO₂CF₂H)₂ for direct difluoromethylation.

    See the paper →
  3. 2012

    Zinc sulfinate toolkit

    Alkyl radicals to heterocycles, in water and air; four reagents already at Sigma-Aldrich.

    See the paper →
  4. 2014

    Palau’chlor

    A practical chlorinating reagent born in total synthesis.

    See the paper →
  5. 2016

    Strain-release amination

    Spring-loaded bonds meet amines.

    See the paper →
  6. 2017

    Heteroatom functionalization

    The full account: alcohols, thiols, acids and a stereospecific cyclopentylation.

    See the paper →
  7. 2025

    Azabicyclobutanes

    Enantiocontrolled azetidine libraries by strain-release functionalization of 1-azabicyclobutanes.

    See the paper →
  8. 2019

    Sulfinates review

    J. Med. Chem.: 40 commercial Diversinates and more than 50 drug-discovery cases.

    See the paper →
  9. 2024

    Anomeric amides

    N–X anomeric amides for electrophilic halogenation.

    See the paper →
  10. 2025

    Sulfonyl hydrazides

    Seven redox-neutral couplings, dump-and-stir.

    See the paper →
  11. 2026

    Alkyl–sulfur

    N₂ extrusion of alkyl hydrazines gives alkyl–sulfur compounds.

    See the paper →
  12. 2021

    1,2-Bicyclopentanes

    Bridge-substituted BCPs as long-sought ortho/meta-arene mimics, with Pfizer.

    See the paper →
  13. 2025

    Propellane-free BCPs

    Dibromocarbene addition to bicyclobutanes gives substituted bicyclopentanes.

    See the paper →
  14. 2026

    Small rings, one step

    Ni-electrocatalytic assembly of 1,1-diaryl cyclobutanes, azetidines and oxetanes.

    See the paper →
Scroll sideways for more →
01 The problem

The last step is the hardest

Medicinal chemists spend their days making small changes to promising molecules: a methyl here, a fluorine-bearing group there, a small ring swapped for another. Each change can alter how a drug is absorbed, how long it lasts and what it hits.

The trouble is that the molecules most useful in medicinal chemistry — nitrogen-rich heterocycles — “are often the least compliant with two-electron functionalization methods.” The lab’s 2019 Journal of Medicinal Chemistry miniperspective puts the test that every new reaction faces in a single question: “Does it work on an unsubstituted pyridine?” The usual workaround is to rebuild the molecule from scratch with the new group already in place, which is slow.

The cost can be startling. The lab’s 2012 Nature paper notes that one simple difluoromethylated pyridine was commercially available at $3,500 per gram. The same paper named the paradox: the very properties that make heterocycles so desirable biologically “render them challenging substrates for direct chemical functionalization,” from poor solubility to poisoning of catalysts.

02 The idea

Zinc sulfinates: radicals in a jar

The path to those reagents began in total synthesis. Work on pyrrole-imidazole alkaloids, including palau’amine, produced a radical-based oxidant that could install a key C–O bond in water. At the same time, conversations with pharmaceutical companies raised a parallel question: might similarly curious radical reactions also work under the nitrogen-rich constraints of modern medicine? The late Francesco Minisci had already shown that radicals have a “unique affinity” for charged heterocycles. After first expanding his reaction to arylboronic acids, the lab turned to a functional group whose radical decomposition pathway had been described, and then largely set aside.

In the 1990s, Bernard Langlois showed that sodium trifluoromethanesulfinate (Na-TFMS), a copper(II) salt and tert-butyl hydroperoxide (TBHP) could trifluoromethylate phenols and anilines. The chemistry “went largely unnoticed at the time, likely due to Langlois’ claim that the chemistry was limited to electron-rich arenes.” The 2019 review notes that, prior to 2012, his sulfinate reagent was “entirely absent from the patent literature.” The lab found that a simple oxidant could engage a wide range of electron-rich and electron-deficient heterocycles, “presumably due to the relatively low homolytic barrier of the sulfinate C–S bond.”

Scheme: a zinc bis(alkanesulfinate) releases an alkyl radical and sulfur dioxide on oxidation with TBHP; the radical attaches to a heterocycle C–H position.
Sulfinates release an alkyl radical and sulfur dioxide when oxidized; the radical adds to the heterocycle at its most reactive C–H position.Diagram: Baran Lab website, after Fujiwara et al., Nature 2012, and Smith et al., J. Med. Chem. 2019.

In 2011 (PNAS) a bench-stable trifluoromethyl radical source added CF3 groups directly to heterocycles at room temperature, on unprotected molecules, at their “innately reactive positions.” A zinc reagent for CF2H, Zn(SO2CF2H)2 or DFMS, followed in 2012 (JACS). Later that year, in Nature, the idea became a toolkit: zinc sulfinate salts that transfer alkyl radicals to heterocycles “in the presence of water and air,” with no protecting groups and even in tandem in one pot. Four of them were already sold by Sigma-Aldrich; a 2013 Nature Protocols paper explained how to make and purify the rest.

Figure 1 of the J. Med. Chem. sulfinates review: palau’amine-inspired C–H oxidation, expansion of the Minisci reaction, Langlois’ 1991 precedent, and a catalogue of 40 commercial Diversinate sulfinates colour-coded as fluoroalkyl, alkyl, heterocyclic, aromatic and linker-type.
A, a radical C–H oxidation from the palau’amine campaign. B, expanding Minisci’s reaction from carboxylic acids to boronic acids. C, Langlois’ sulfinate precedent, long thought limited to electron-rich arenes, and the weaker C–S bond that makes the reagents practical. D, 40 commercial sulfinates, sold as Diversinates, for early- and late-stage arene modification.Figure 1 from Smith, Dixon, deGruyter & Baran, “Alkyl Sulfinates: Radical Precursors Enabling Drug Discovery,” J. Med. Chem. 2019, doi:10.1021/acs.jmedchem.8b01303. © American Chemical Society. Reproduced by the authors for this site.
Graphical abstract: Practical and Innate Carbon–Hydrogen Functionalization of Heterocycles
Practical and innate C–H functionalization of heterocycles (Nature 2012): the zinc sulfinate toolkit. Graphical abstract from Practical and Innate Carbon–Hydrogen Functionalization of Heterocycles, Nature 2012 · doi:10.1038/nature11680

In commercial partnership with MilliporeSigma, the lab went on to develop 40 sulfinates for early- and late-stage arene modification: fluoroalkyl, alkyl, heterocyclic, aromatic and linker-type reagents, “each of which has seen near-immediate adoption by the medicinal chemistry community.” The experimental protocol is deliberately unfussy. The review emphasizes that the setup “requires no rigor” about an open flask, solvent purification (provided radical inhibitors are absent) or purity of starting materials — one-pot sequences are well tolerated. The procedure calls only for the substrate, oxidant (typically TBHP), solvent and the sulfinate; a Brønsted or Lewis acid can be added to improve yields or influence selectivity, but is not required.

Adoption showed up in the order book. By 2016, the lab’s JACS Perspective on radicals recorded, demand for DFMS had prompted large-scale production in 1 kg bottles, the reagents were sold in more than 27 countries, and roughly 80% of purchases were made by pharmaceutical companies. The same Perspective notes that sulfinate C–H functionalization works in unforgiving media, including cell lysate, oolong tea and a lactamase buffer, a robustness it likens to a “click” reaction.

“Sulfinates (now marketed as Diversinates) have seen alacritous adoption by the medicinal chemistry community, as evidenced by the recent outpour of both patent and primary reports.”

03 The trends

Reading the regioselectivity

The 2019 review gathered more than 50 examples from industry and academia over the previous five years, “with an eye toward the identification of robust and predictable trends in reactivity.” Though “occasionally capricious,” the behavior of nitrogenous heterocycles with radical intermediates is “not without guiding principles.”

Adding an oxidant to a sulfinate salt generates a carbon-centred radical. Whether that radical is nucleophilic (alkyl, aryl, CF2H) or electrophilic (for example CF3), and whether the reaction is run acidic or neutral, decides where it adds. For nucleophilic radicals, an electron-poor heterocycle under acidic conditions is functionalized next to the nitrogen (C2); in a neutral medium the selectivity flips toward a radical conjugate addition (C3). Electron-donating substituents can hamper, or even preclude, reaction with nucleophilic radicals. Electrophilic radicals show the same preference on electron-deficient heteroarenes regardless of pH, though the effect is less pronounced. The true divergence appears when an electrophilic radical meets a heteroarene that bears a donor group: then the regioselectivity typical of electrophilic aromatic substitution takes over.

Figure 2 of the J. Med. Chem. sulfinates review: regioselectivity guidelines for nucleophilic versus electrophilic radicals, a four-step reactivity flowchart, and two radical-retrosynthesis case studies, including a bipyridine made in 3% yield by a polar route versus a one-pot sulfinate sequence, and Merck’s difluoromethylated pyrazolopyridine.
A, guidelines for nucleophilic versus electrophilic radicals on pyridines. B, a reactivity flowchart, even within a single sulfinate, for methyl 3-methylpicolinate. C, two radical retrosyntheses: a trifluoromethylcyclopropyl bipyridine that a polar route delivered in 3% yield after several purifications, and Merck’s difluoromethylated pyrazolopyridine, where DFMS replaced a string of non-strategic redox steps.Figure 2 from Smith, Dixon, deGruyter & Baran, “Alkyl Sulfinates: Radical Precursors Enabling Drug Discovery,” J. Med. Chem. 2019, doi:10.1021/acs.jmedchem.8b01303. © American Chemical Society. Reproduced by the authors for this site.

Those rules turn into shorter routes. The existing polar synthesis of bipyridine 3 installed a trifluoromethylcyclopropyl group over several steps from a dibromopyridine, then a borylation and a cross-coupling, and finished in 3% yield after multiple chromatographies. Treating a pyridine boronic ester with sulfinate 8 enabled a one-pot trifluoromethylcyclopropanation / Suzuki–Miyaura sequence and gave the same target after a single purification. Shortly afterwards, Merck disclosed two routes to a difluoromethylated pyrazolopyridine; the more expeditious one used DFMS, while the polar alternative required a number of non-strategic redox manipulations.

⚗ For chemists

Predicting the site, and using mixed products

Because sulfinate-derived radicals add at the innately reactive positions of the heterocycle, selectivity can often be predicted from the substrate rather than enforced with directing groups. The review highlights a practical shortcut used on a Gilead intermediate: basic 13C NMR predictions in ChemDraw flag the most electron-rich (furthest upfield) site, which is where an electrophilic trifluoromethyl radical prefers to add. Imperfect selectivity is not always a failure. In one Actelion example, a cyanopyridine was difluoromethylated at both the expected C2 position and C4; both products proved useful for structure–activity work. The radical’s character can also be chosen on purpose. In a Kyungpook National University study of ERRγ inverse agonists, otherwise identical conditions sent an electrophilic CF3 radical from TFMS onto an electron-rich phenol, while a nucleophilic isopropyl radical from sodium isopropylsulfinate (IPS) added exclusively at C2 of the embedded pyridine.

04 In practice

An afternoon, not a total synthesis

In medicinal chemistry the typical sulfinate reaction is either early-stage — decorating a building block that then fans out into a library — or late-stage, on an advanced intermediate. The review’s ten early-stage patent examples are not esoteric models. A difluoromethylated pyridine made this way was the primary building block of 40 analogues. The same difluoromethylation was used by H. Lundbeck A/S to reach a precursor that supported three medicinal leads. Without this innate C–H functionalization, the review notes, a “total synthesis” of each analogue would have been required, and “in the midst of a discovery campaign, it is entirely possible that they would not have been pursued at all.”

Figure 4 of the J. Med. Chem. sulfinates review: a Gilead intermediate with ChemDraw carbon-13 chemical shifts predicting the site of trifluoromethylation, and late-stage patented examples from Peleton, Astellas, Bayer, Janssen, Actelion, Roche, Konica Minolta and Kyungpook National University, including a case where TFMS and isopropylsulfinate functionalize different rings of the same scaffold.
A, site prediction on a Gilead Sciences intermediate: the most upfield carbon is where the electrophilic CF3 radical adds. B, late-stage examples from the patent literature, including Actelion’s two useful regioisomers and the Kyungpook case in which the choice of sulfinate alone switches the ring that is functionalized.Figure 4 from Smith, Dixon, deGruyter & Baran, “Alkyl Sulfinates: Radical Precursors Enabling Drug Discovery,” J. Med. Chem. 2019, doi:10.1021/acs.jmedchem.8b01303. © American Chemical Society. Reproduced by the authors for this site.

Pyridine is only a fraction of drug-lead space. Pyrazoles, pyrroles and bicyclic heteroarenes also undergo predictable early- or late-stage (fluoro)alkylation. Alternative polar routes, the review argues, would almost certainly be long enough to discourage immediate pursuit. The reactions remain remarkably selective even on sterically encumbered leads from Ono Pharmaceutical and the Shanghai Institute of Materia Medica. Yields are often modest and unoptimized; the value on display is “rapid, predictable expansion of developing pharmaceutical libraries.” Sulfinates have also been used as conjugation handles — for example an appended azido group, in work from Konica Minolta — for chemical biology.

Figure 6 of the J. Med. Chem. sulfinates review: late-stage diversification of drug-like molecules at Boehringer Ingelheim, including four sulfinates on one pyrimidine; improved yields with an iron(III) additive; modification of agelastatin and cinchona alkaloids; and a Shabat sulfinate used as a bioconjugation handle.
A, late-stage use at Boehringer Ingelheim, including four distinct sulfinates on one pyrimidine, each preferring the most electrophilic position. B, Fe(III) salts, usually Fe(acac)3, can improve isolated yields. C, sulfinate modification of agelastatin and cinchona alkaloids. D, a masked-ketone sulfinate as a tag for heterocyclic and peptide bioconjugation.Figure 6 from Smith, Dixon, deGruyter & Baran, “Alkyl Sulfinates: Radical Precursors Enabling Drug Discovery,” J. Med. Chem. 2019, doi:10.1021/acs.jmedchem.8b01303. © American Chemical Society. Reproduced by the authors for this site.

Boehringer Ingelheim reported the productive coupling of four distinct sulfinates to a single pyrimidine, each preferring the most electrophilic position. In a systematic study of late-stage selectivity on drug candidates, Kuttruff and co-workers found that Fe(III) salts, usually Fe(acac)3, can improve yields. Academic groups used the same reagents on natural products: the Waldmann laboratory prepared cinchona alkaloid (quinine) analogues and found that three of them showed enhanced selectivity in autophagy inhibition; the Molinski group made agelastatin analogues and noted the value of the mild TBHP conditions compared with photoinduced electron-transfer initiation. Shabat and co-workers exploited a masked methyl ketone sulfinate for heterocyclic tagging and peptide bioconjugation. Electrochemical and photochemical initiation can also be useful in specific cases.

“Sulfinates offer medicinal chemists an opportunistic retrosynthetic approach; disconnection priority can be placed on the parent scaffold, while peripheral substituents are duly treated as an afterthought rather than a primary consideration.”

Graphical abstract: Alkyl Sulfinates: Radical Precursors Enabling Drug Discovery
The medicinal chemist’s guide to sulfinates (J. Med. Chem. 2019): more than 50 real applications, the trends behind them, and the Diversinates catalogue. Graphical abstract from Alkyl Sulfinates: Radical Precursors Enabling Drug Discovery, J. Med. Chem. 2019 · doi:10.1021/acs.jmedchem.8b01303
05 More reagents

Inspired by natural products, built for med chem

Several of the lab’s reagents were spin-offs of total synthesis. Palau’chlor (CBMG, 2014), a guanidine-based chlorinating reagent, was “inspired by a key chlorospirocyclization en route to pyrrole imidazole alkaloids,” the family that includes palau’amine. Chlorinated heteroarenes matter twice over: the chlorine tunes a molecule’s electronics and is a handle for later cross-coupling.

Strain-release amination answered a request from industry. Small strained rings such as bicyclo[1.1.1]pentanes, azetidines and cyclobutanes are prized by medicinal chemists as bioisosteres, but they were hard to attach. The 2016 Science paper describes how difficulties in making bicyclo[1.1.1]pentan-1-amine at Pfizer had led to the abandonment of a lead oncology candidate. The answer was to let amines react directly with the most strained C–C bond of [1.1.1]propellane, which stores roughly 60 kcal/mol, using “turbo amides.” The full study that followed in 2017 extended the idea to other heteroatoms and introduced a stereospecific strain-release cyclopentylation. That work helped set this area of chemistry in motion. In the years since, hundreds of papers have taken up strain-release functionalization of small rings: bicyclobutanes, [1.1.1]propellane and the bicyclo[1.1.1]pentanes (BCPs) derived from it, azabicyclobutanes and others. A 2020 review by Turkowska, Durka and Gryko, writing in Chemical Communications, put the 2016 work in those terms: “the real renaissance of strain-release driven transformations was launched by Baran and co-workers,” who, the authors note, also described the rings as “spring-loaded” molecules. The history, and the numbers, are in the next chapter, From curiosity to reagent.

Scheme 1 of the 2020 Chemical Communications review: [1.1.1]propellane (TCP), bicyclo[1.1.0]butane (BCB), 1-azabicyclo[1.1.0]butane (ABB) and housane, with ring-strain energies, central-bond lengths and the less-strained rings formed when the bridging bond is released.
The strained rings at the center of the 2016 method, and the less-strained skeletons formed when the bridging bond is released. Strain energies and bond lengths as compiled by Turkowska, Durka and Gryko.Scheme 1 from Turkowska, Durka & Gryko, “Strain release – an old tool for new transformations,” Chem. Commun. 2020, doi:10.1039/d0cc01771j. © The Royal Society of Chemistry 2020. Reproduced by the authors for this site.

In 2024 a Nature Chemistry paper added N–X anomeric amides as electrophilic halogenation reagents.

06 Spring-loaded

From curiosity to reagent

For more than three decades after it was first made, [1.1.1]propellane was studied far more than it was used. It tested theories of chemical bonding and served as a starting point for molecular rods, and physical organic chemists knew it far better than medicinal chemists did. In 2016 the lab, working with Pfizer, turned it from a curiosity into a reagent.

The chemistry began at Yale. Kenneth B. Wiberg, a physical organic chemist who spent much of his career on strained hydrocarbons, prepared the first bicyclo[1.1.0]butane in 1959 (J. Am. Chem. Soc. 1959) and bicyclo[1.1.1]pentane in 1964 (Tetrahedron Lett. 1964). [1.1.1]Propellane goes one step further: its two bridgehead carbons are joined directly, and every other bond at each of them points to the same side. Most chemists assumed it was too strained to exist. Wiberg’s calculations found no easy path by which it would fall apart, and in 1982 he and Frederick Walker made it (J. Am. Chem. Soc. 1982). Three years later Günter Szeimies and co-workers reported a new route to the parent hydrocarbon (J. Am. Chem. Soc. 1985), and modified versions of that route remain the most common way to make it. The central bond proved reactive. Radicals added across it (Tetrahedron Lett. 1986; J. Am. Chem. Soc. 1990). So did tert-butyllithium, which Ernest Della and colleagues found would generate propellane from a bromobicyclopentane and then add to it (Tetrahedron Lett. 1990). Piotr Kaszynski and Josef Michl used repeated additions to build rigid oligomers they called [n]staffanes, “a molecular-size ‘Tinkertoy’ construction set for nanotechnology” (J. Am. Chem. Soc. 1988). They later collected two decades of this work in Chemical Reviews (2000). Wiberg died in May 2026, at the age of 98.

For most of that time the literature was about bonding, spectra and materials. Before 2012, only 41% of the papers we could find that mention bicyclopentanes or [1.1.1]propellane are classified as organic chemistry. The rest belong mostly to physics, spectroscopy, and inorganic and theoretical chemistry. The lab’s 2017 account said the same of strained hydrocarbons in general. This science, it noted, “has largely been buried in the realm of physical organic chemistry literature” (J. Am. Chem. Soc. 2017). Two reviews use the same word for the period. A 2017 survey of propellanes is titled “From a Chemical Curiosity to ‘Explosive’ Materials” (Angew. Chem. Int. Ed. 2017), and a 2022 review of bicyclobutanes is subtitled “from curiosities to versatile reagents” (Chem. Sci. 2022).

Medicinal chemists noticed early, but only now and then. In 1993 Michael Barbachyn and colleagues reported a quinolone antibacterial carrying a bicyclo[1.1.1]pent-1-yl group (Bioorg. Med. Chem. Lett. 1993). In 1996 Roberto Pellicciari’s group made a bicyclopentane analogue of (S)-4-carboxyphenylglycine, a new kind of antagonist for group I metabotropic glutamate receptors (J. Med. Chem. 1996). A 2023 review notes that this result was “largely overlooked outside of this field for over a decade” (Shire & Anderson, JACS Au 2023). Drug discovery took notice in 2012. Antonia Stepan and colleagues at Pfizer replaced the central fluorophenyl ring of the γ-secretase inhibitor avagacestat (BMS-708,163) with a bicyclo[1.1.1]pentane (J. Med. Chem. 2012). The analogue was as potent as the original, more soluble and more permeable, and reached about four times the exposure in mice. In the same review’s words, “It was not until 2012 that interest in this field was truly kindled.”

Wanting the ring was easier than making it. The building block medicinal chemists most wanted, bicyclo[1.1.1]pentan-1-amine, had been made by several multistep routes, through bridgehead acids, azides, stannanes or hydrazines. Pfizer’s best route was a hydrohydrazination of propellane (Bunker et al., Org. Lett. 2011). The company’s process chemists still judged it unscalable: the propellane had to be distilled, the key step gave large exotherms, and the later intermediates were high-energy hydrazine derivatives. The 2016 Science paper records what this cost: difficulties in preparing the amine “led to the abandonment of a lead oncology clinical candidate.”

Pfizer brought the problem to the lab. The lab’s idea was to let an amine break propellane’s central bond, which stores roughly 60 kcal/mol, directly. There was little precedent. Organolithium reagents were known to add across the bond. Amines and amine surrogates added to another strained hydrocarbon, 1,3-dehydroadamantane, but only when they carried an acidic N–H (Tetrahedron Lett. 1983). In Szeimies’ laboratory, attempts to add magnesium amides to propellane had failed. A lithium amide gave about 20% of the product. The breakthrough came from Paul Knochel’s “turbo Grignard” (Angew. Chem. Int. Ed. 2004). Dibenzylamine treated with i-PrMgCl·LiCl became a “turbo amide,” which opened propellane in 73% yield. With phenyllithium used to make the propellane, the sequence ran at 60% on more than 100 g, and an outside vendor then scaled it up.

Gianatassio, Lopchuk and colleagues, with co-authors at Pfizer, called the general idea strain-release amination, and the reagents “strain release reagents.” Twenty-nine amines were “propellerized” directly, and six commercial drugs gained the ring in a single late-stage step. An azabicyclobutane did the same for azetidines, with 18 amines, and arylsulfonyl bicyclobutanes did it for cyclobutanes, with 16. Yehiel Gaoni had added benzylamine to such sulfones using the amine as the solvent at 140 °C (Tetrahedron Lett. 1988). The redesigned reagents worked under mild conditions and needed only a limiting amount of amine. One of them labelled the cysteine of a peptide completely selectively, in 91% isolated yield. A maleimide, the usual reagent for the job, gave multiple adducts with a cysteine-free peptide within an hour. The full account in 2017 added alcohols, thiols and acids, as well as a stereospecific “cyclopentylation.” It also records where the work came from: “the story of strain-release functionalization began in our lab when Pfizer approached us.”

The ring also turned up in the lab’s decarboxylative cross-coupling papers. In that chemistry a carboxylic acid is activated as a redox-active ester and becomes a carbon radical, and bridgehead acids are among the hardest substrates. In the 2016 iron-catalyzed coupling with arylzinc reagents, methyl 3-phenylbicyclo[1.1.1]pentane-1-carboxylate formed in 35% yield, against less than 2% under nickel catalysis. The authors noted that bicyclo[1.1.1] and cubane frameworks “have been outside of the realm of C–C coupling, even with alkyl halide starting materials” (J. Am. Chem. Soc. 2016). A 2018 nickel-promoted radical addition to a chiral sulfinimine gave a protected bicyclopentyl amino acid in 54% yield (Angew. Chem. Int. Ed. 2018). The same paper made a 3-fluorobicyclopentyl amino acid, Fmoc-protected, in 23% overall yield from bicyclo[1.1.1]pentane-1,3-dicarboxylic acid; the previous route had taken nine steps and given 2%. The 2021 platform for 1,2-difunctionalized bicyclopentanes depended on the same chemistry. A bridge-substituted acid was converted to its redox-active ester and borylated under the lab’s copper-catalyzed conditions, and decarboxylative cross-coupling was “essential to generating the aryl–BCP linkage” in the bioisosteres that followed (PNAS 2021). In the 2022 silver–nickel electrocatalytic arylation, a bicyclopentyl ester coupled with an iodoimidazole in 32% yield, or 16% from the bromide. Four benchmark methods tested alongside it gave none, or traces (J. Am. Chem. Soc. 2022).

How much did all this matter? The publication record gives a partial answer.

Bicyclopentanes, from curiosity to reagent, 1980–2026

2025 160 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellaneFull text, title or abstract; research articles and reviews (OpenAlex)

2016 · strain release 2012 · Pfizer’s BCP 1982 · Wiberg’s propellane 0 50 100 150 200 1980: 0 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1981: 2 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1982: 3 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1983: 1 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1984: 8 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1985: 7 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1986: 7 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1987: 5 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1988: 12 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1989: 10 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1990: 21 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1991: 20 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1992: 17 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1993: 11 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1994: 16 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1995: 13 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1996: 5 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1997: 9 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1998: 11 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane1999: 4 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2000: 11 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2001: 15 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2002: 4 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2003: 9 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2004: 11 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2005: 8 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2006: 4 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2007: 6 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2008: 4 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2009: 6 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2010: 15 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2011: 10 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2012: 12 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2013: 8 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2014: 14 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2015: 11 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2016: 11 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2017: 16 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2018: 16 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2019: 29 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2020: 43 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2021: 68 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2022: 63 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2023: 142 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2024: 151 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2025: 160 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane2026: 193 papers mention bicyclo[1.1.1]pentanes or [1.1.1]propellane (partial year, counted on 16 November 2026) 0 50 100 150 1980: 0 BCP papers in organic chemistry1981: 1 BCP papers in organic chemistry1982: 1 BCP papers in organic chemistry1983: 0 BCP papers in organic chemistry1984: 1 BCP papers in organic chemistry1985: 2 BCP papers in organic chemistry1986: 3 BCP papers in organic chemistry1987: 3 BCP papers in organic chemistry1988: 7 BCP papers in organic chemistry1989: 6 BCP papers in organic chemistry1990: 11 BCP papers in organic chemistry1991: 9 BCP papers in organic chemistry1992: 7 BCP papers in organic chemistry1993: 3 BCP papers in organic chemistry1994: 5 BCP papers in organic chemistry1995: 7 BCP papers in organic chemistry1996: 3 BCP papers in organic chemistry1997: 5 BCP papers in organic chemistry1998: 4 BCP papers in organic chemistry1999: 3 BCP papers in organic chemistry2000: 3 BCP papers in organic chemistry2001: 7 BCP papers in organic chemistry2002: 4 BCP papers in organic chemistry2003: 1 BCP papers in organic chemistry2004: 7 BCP papers in organic chemistry2005: 3 BCP papers in organic chemistry2006: 2 BCP papers in organic chemistry2007: 1 BCP papers in organic chemistry2008: 0 BCP papers in organic chemistry2009: 0 BCP papers in organic chemistry2010: 5 BCP papers in organic chemistry2011: 2 BCP papers in organic chemistry2012: 3 BCP papers in organic chemistry2013: 3 BCP papers in organic chemistry2014: 3 BCP papers in organic chemistry2015: 3 BCP papers in organic chemistry2016: 6 BCP papers in organic chemistry2017: 8 BCP papers in organic chemistry2018: 7 BCP papers in organic chemistry2019: 19 BCP papers in organic chemistry2020: 30 BCP papers in organic chemistry2021: 46 BCP papers in organic chemistry2022: 44 BCP papers in organic chemistry2023: 104 BCP papers in organic chemistry2024: 115 BCP papers in organic chemistry2025: 134 BCP papers in organic chemistry2026: 149 BCP papers in organic chemistry (partial year, counted on 16 November 2026) 0 50 100 150 200 1980: 0 papers pair “strain-release” with these rings1981: 1 papers pair “strain-release” with these rings1982: 0 papers pair “strain-release” with these rings1983: 0 papers pair “strain-release” with these rings1984: 0 papers pair “strain-release” with these rings1985: 0 papers pair “strain-release” with these rings1986: 0 papers pair “strain-release” with these rings1987: 0 papers pair “strain-release” with these rings1988: 0 papers pair “strain-release” with these rings1989: 0 papers pair “strain-release” with these rings1990: 0 papers pair “strain-release” with these rings1991: 0 papers pair “strain-release” with these rings1992: 0 papers pair “strain-release” with these rings1993: 0 papers pair “strain-release” with these rings1994: 0 papers pair “strain-release” with these rings1995: 0 papers pair “strain-release” with these rings1996: 1 papers pair “strain-release” with these rings1997: 0 papers pair “strain-release” with these rings1998: 0 papers pair “strain-release” with these rings1999: 0 papers pair “strain-release” with these rings2000: 0 papers pair “strain-release” with these rings2001: 0 papers pair “strain-release” with these rings2002: 0 papers pair “strain-release” with these rings2003: 0 papers pair “strain-release” with these rings2004: 0 papers pair “strain-release” with these rings2005: 0 papers pair “strain-release” with these rings2006: 0 papers pair “strain-release” with these rings2007: 0 papers pair “strain-release” with these rings2008: 0 papers pair “strain-release” with these rings2009: 0 papers pair “strain-release” with these rings2010: 0 papers pair “strain-release” with these rings2011: 0 papers pair “strain-release” with these rings2012: 0 papers pair “strain-release” with these rings2013: 0 papers pair “strain-release” with these rings2014: 0 papers pair “strain-release” with these rings2015: 0 papers pair “strain-release” with these rings2016: 2 papers pair “strain-release” with these rings2017: 2 papers pair “strain-release” with these rings2018: 3 papers pair “strain-release” with these rings2019: 11 papers pair “strain-release” with these rings2020: 11 papers pair “strain-release” with these rings2021: 19 papers pair “strain-release” with these rings2022: 31 papers pair “strain-release” with these rings2023: 50 papers pair “strain-release” with these rings2024: 85 papers pair “strain-release” with these rings2025: 124 papers pair “strain-release” with these rings2026: 153 papers pair “strain-release” with these rings (partial year, counted on 16 November 2026) 0 20 40 60 1980: 0 per 100 BCP papers cite a lab paper that makes BCPs1981: 0 per 100 BCP papers cite a lab paper that makes BCPs1982: 0 per 100 BCP papers cite a lab paper that makes BCPs1983: 0 per 100 BCP papers cite a lab paper that makes BCPs1984: 0 per 100 BCP papers cite a lab paper that makes BCPs1985: 0 per 100 BCP papers cite a lab paper that makes BCPs1986: 0 per 100 BCP papers cite a lab paper that makes BCPs1987: 0 per 100 BCP papers cite a lab paper that makes BCPs1988: 0 per 100 BCP papers cite a lab paper that makes BCPs1989: 0 per 100 BCP papers cite a lab paper that makes BCPs1990: 0 per 100 BCP papers cite a lab paper that makes BCPs1991: 0 per 100 BCP papers cite a lab paper that makes BCPs1992: 0 per 100 BCP papers cite a lab paper that makes BCPs1993: 0 per 100 BCP papers cite a lab paper that makes BCPs1994: 0 per 100 BCP papers cite a lab paper that makes BCPs1995: 0 per 100 BCP papers cite a lab paper that makes BCPs1996: 0 per 100 BCP papers cite a lab paper that makes BCPs1997: 0 per 100 BCP papers cite a lab paper that makes BCPs1998: 0 per 100 BCP papers cite a lab paper that makes BCPs1999: 0 per 100 BCP papers cite a lab paper that makes BCPs2000: 0 per 100 BCP papers cite a lab paper that makes BCPs2001: 0 per 100 BCP papers cite a lab paper that makes BCPs2002: 0 per 100 BCP papers cite a lab paper that makes BCPs2003: 0 per 100 BCP papers cite a lab paper that makes BCPs2004: 0 per 100 BCP papers cite a lab paper that makes BCPs2005: 0 per 100 BCP papers cite a lab paper that makes BCPs2006: 0 per 100 BCP papers cite a lab paper that makes BCPs2007: 0 per 100 BCP papers cite a lab paper that makes BCPs2008: 0 per 100 BCP papers cite a lab paper that makes BCPs2009: 0 per 100 BCP papers cite a lab paper that makes BCPs2010: 0 per 100 BCP papers cite a lab paper that makes BCPs2011: 0 per 100 BCP papers cite a lab paper that makes BCPs2012: 0 per 100 BCP papers cite a lab paper that makes BCPs2013: 0 per 100 BCP papers cite a lab paper that makes BCPs2014: 0 per 100 BCP papers cite a lab paper that makes BCPs2015: 0 per 100 BCP papers cite a lab paper that makes BCPs2016: 18.2 per 100 BCP papers cite a lab paper that makes BCPs2017: 43.8 per 100 BCP papers cite a lab paper that makes BCPs2018: 31.2 per 100 BCP papers cite a lab paper that makes BCPs2019: 51.7 per 100 BCP papers cite a lab paper that makes BCPs2020: 46.5 per 100 BCP papers cite a lab paper that makes BCPs2021: 29.4 per 100 BCP papers cite a lab paper that makes BCPs2022: 28.6 per 100 BCP papers cite a lab paper that makes BCPs2023: 31.7 per 100 BCP papers cite a lab paper that makes BCPs2024: 25.8 per 100 BCP papers cite a lab paper that makes BCPs2025: 30 per 100 BCP papers cite a lab paper that makes BCPs2026: 22.8 per 100 BCP papers cite a lab paper that makes BCPs (partial year, counted on 16 November 2026) 0 25 50 75 100 1980: 0 papers cite strain-release amination1981: 0 papers cite strain-release amination1982: 0 papers cite strain-release amination1983: 0 papers cite strain-release amination1984: 0 papers cite strain-release amination1985: 0 papers cite strain-release amination1986: 0 papers cite strain-release amination1987: 0 papers cite strain-release amination1988: 0 papers cite strain-release amination1989: 0 papers cite strain-release amination1990: 0 papers cite strain-release amination1991: 0 papers cite strain-release amination1992: 0 papers cite strain-release amination1993: 0 papers cite strain-release amination1994: 0 papers cite strain-release amination1995: 0 papers cite strain-release amination1996: 0 papers cite strain-release amination1997: 0 papers cite strain-release amination1998: 0 papers cite strain-release amination1999: 0 papers cite strain-release amination2000: 0 papers cite strain-release amination2001: 0 papers cite strain-release amination2002: 0 papers cite strain-release amination2003: 0 papers cite strain-release amination2004: 0 papers cite strain-release amination2005: 0 papers cite strain-release amination2006: 0 papers cite strain-release amination2007: 0 papers cite strain-release amination2008: 0 papers cite strain-release amination2009: 0 papers cite strain-release amination2010: 0 papers cite strain-release amination2011: 0 papers cite strain-release amination2012: 0 papers cite strain-release amination2013: 0 papers cite strain-release amination2014: 0 papers cite strain-release amination2015: 0 papers cite strain-release amination2016: 13 papers cite strain-release amination2017: 18 papers cite strain-release amination2018: 21 papers cite strain-release amination2019: 34 papers cite strain-release amination2020: 41 papers cite strain-release amination2021: 34 papers cite strain-release amination2022: 40 papers cite strain-release amination2023: 61 papers cite strain-release amination2024: 81 papers cite strain-release amination2025: 93 papers cite strain-release amination2026: 89 papers cite strain-release amination (partial year, counted on 16 November 2026) 0 20 40 60 80 1980: 0 papers cite the Pfizer BCP paper1981: 0 papers cite the Pfizer BCP paper1982: 0 papers cite the Pfizer BCP paper1983: 0 papers cite the Pfizer BCP paper1984: 0 papers cite the Pfizer BCP paper1985: 0 papers cite the Pfizer BCP paper1986: 0 papers cite the Pfizer BCP paper1987: 0 papers cite the Pfizer BCP paper1988: 0 papers cite the Pfizer BCP paper1989: 0 papers cite the Pfizer BCP paper1990: 0 papers cite the Pfizer BCP paper1991: 0 papers cite the Pfizer BCP paper1992: 0 papers cite the Pfizer BCP paper1993: 0 papers cite the Pfizer BCP paper1994: 0 papers cite the Pfizer BCP paper1995: 0 papers cite the Pfizer BCP paper1996: 0 papers cite the Pfizer BCP paper1997: 0 papers cite the Pfizer BCP paper1998: 0 papers cite the Pfizer BCP paper1999: 0 papers cite the Pfizer BCP paper2000: 0 papers cite the Pfizer BCP paper2001: 0 papers cite the Pfizer BCP paper2002: 0 papers cite the Pfizer BCP paper2003: 0 papers cite the Pfizer BCP paper2004: 0 papers cite the Pfizer BCP paper2005: 0 papers cite the Pfizer BCP paper2006: 0 papers cite the Pfizer BCP paper2007: 0 papers cite the Pfizer BCP paper2008: 0 papers cite the Pfizer BCP paper2009: 0 papers cite the Pfizer BCP paper2010: 0 papers cite the Pfizer BCP paper2011: 0 papers cite the Pfizer BCP paper2012: 3 papers cite the Pfizer BCP paper2013: 2 papers cite the Pfizer BCP paper2014: 5 papers cite the Pfizer BCP paper2015: 8 papers cite the Pfizer BCP paper2016: 12 papers cite the Pfizer BCP paper2017: 10 papers cite the Pfizer BCP paper2018: 13 papers cite the Pfizer BCP paper2019: 18 papers cite the Pfizer BCP paper2020: 37 papers cite the Pfizer BCP paper2021: 25 papers cite the Pfizer BCP paper2022: 29 papers cite the Pfizer BCP paper2023: 43 papers cite the Pfizer BCP paper2024: 66 papers cite the Pfizer BCP paper2025: 74 papers cite the Pfizer BCP paper2026: 71 papers cite the Pfizer BCP paper (partial year, counted on 16 November 2026) 0 50 100 150 1980: 0 papers mention BCPs or [1.1.1]propellane1981: 0 papers mention BCPs or [1.1.1]propellane1982: 0 papers mention BCPs or [1.1.1]propellane1983: 0 papers mention BCPs or [1.1.1]propellane1984: 0 papers mention BCPs or [1.1.1]propellane1985: 0 papers mention BCPs or [1.1.1]propellane1986: 0 papers mention BCPs or [1.1.1]propellane1987: 0 papers mention BCPs or [1.1.1]propellane1988: 0 papers mention BCPs or [1.1.1]propellane1989: 0 papers mention BCPs or [1.1.1]propellane1990: 0 papers mention BCPs or [1.1.1]propellane1991: 1 papers mention BCPs or [1.1.1]propellane1992: 0 papers mention BCPs or [1.1.1]propellane1993: 0 papers mention BCPs or [1.1.1]propellane1994: 0 papers mention BCPs or [1.1.1]propellane1995: 1 papers mention BCPs or [1.1.1]propellane1996: 2 papers mention BCPs or [1.1.1]propellane1997: 1 papers mention BCPs or [1.1.1]propellane1998: 1 papers mention BCPs or [1.1.1]propellane1999: 1 papers mention BCPs or [1.1.1]propellane2000: 3 papers mention BCPs or [1.1.1]propellane2001: 4 papers mention BCPs or [1.1.1]propellane2002: 3 papers mention BCPs or [1.1.1]propellane2003: 0 papers mention BCPs or [1.1.1]propellane2004: 2 papers mention BCPs or [1.1.1]propellane2005: 3 papers mention BCPs or [1.1.1]propellane2006: 2 papers mention BCPs or [1.1.1]propellane2007: 6 papers mention BCPs or [1.1.1]propellane2008: 1 papers mention BCPs or [1.1.1]propellane2009: 8 papers mention BCPs or [1.1.1]propellane2010: 4 papers mention BCPs or [1.1.1]propellane2011: 4 papers mention BCPs or [1.1.1]propellane2012: 3 papers mention BCPs or [1.1.1]propellane2013: 1 papers mention BCPs or [1.1.1]propellane2014: 7 papers mention BCPs or [1.1.1]propellane2015: 7 papers mention BCPs or [1.1.1]propellane2016: 7 papers mention BCPs or [1.1.1]propellane2017: 10 papers mention BCPs or [1.1.1]propellane2018: 13 papers mention BCPs or [1.1.1]propellane2019: 20 papers mention BCPs or [1.1.1]propellane2020: 30 papers mention BCPs or [1.1.1]propellane2021: 44 papers mention BCPs or [1.1.1]propellane2022: 47 papers mention BCPs or [1.1.1]propellane2023: 73 papers mention BCPs or [1.1.1]propellane2024: 83 papers mention BCPs or [1.1.1]propellane2025: 111 papers mention BCPs or [1.1.1]propellane2026: 110 papers mention BCPs or [1.1.1]propellane (partial year, counted on 16 November 2026) 1980198519901995200020052010201520202025
Show the numbers
YearPapers on BCPs and propellaneIn organic chemistry…that say “strain-release”Share citing the labCitations: Science 2016Citations: Pfizer 2012Second index: Europe PMC
19800000000
19812110000
19823100000
19831000000
19848100000
19857200000
19867300000
19875300000
198812700000
198910600000
1990211100000
199120900001
199217700000
199311300000
199416500000
199513700001
19965310002
19979500001
199811400001
19994300001
200011300003
200115700004
20024400003
20039100000
200411700002
20058300003
20064200002
20076100006
20084000001
20096000008
201015500004
201110200004
201212300033
20138300021
201414300057
201511300087
2016116218.213127
2017168243.8181010
2018167331.2211313
201929191151.7341820
202043301146.5413730
202168461929.4342544
202263443128.6402947
20231421045031.7614373
20241511158525.8816683
2025160134124309374111
2026*19314915322.88971110
Total1,222790493359.7525416613

* 2026: partial year, counted on 16 November 2026.

Each bar counts research articles and reviews in OpenAlex whose indexed full text, title or abstract names bicyclo[1.1.1]pentane(s), a bicyclo[1.1.1]pentyl group or [1.1.1]propellane. Preprints, highlights and duplicate language editions are excluded. Only part of the literature has indexed full text, so every count is a lower bound. Over 2016–2025 the index’s organic chemistry full texts roughly doubled, while these papers rose about fifteenfold. The two later milestones are four years apart, and the data cannot cleanly separate their effects: Pfizer showed why chemists wanted the ring, and strain-release amination gave them a general way to install it.Source: OpenAlex and Europe PMC, queried 16 November 2026. Milestones: Wiberg & Walker, JACS 1982; Stepan et al., J. Med. Chem. 2012; Gianatassio et al., Science 2016.

The curve has three phases. Wiberg’s era shows as a small rise around 1990, about twenty papers a year. A long plateau follows: about nine papers a year from 2000 to 2015, only three of them in organic chemistry. Then the count climbs, from 11 papers in 2016 to 29 in 2019, 68 in 2021 and 160 in 2025, with 193 already counted in 2026. Over the same period the index’s organic chemistry full texts only doubled. Our count for 2012–2022 is consistent with the 2023 review’s estimate of “over 250 papers involving BCPs in the primary chemical literature.” Almost none of the growth is the lab’s own: 888 of the 892 papers since 2016 have no author from the group. The phrase has a clear starting point. In Europe PMC, no paper before the January 2016 Science paper pairs “strain-release” with propellane, bicyclobutane or bicyclopentane. Physical organic chemists had used the words to analyze reaction rates, as in a 1996 paper titled “Strain release is not enough,” but not as the name of a synthetic method. Since 2016, OpenAlex counts nearly 500 papers that pair them.

The chart cannot settle everything. The Pfizer paper and the Science paper are four years apart, and the steepest rise begins around 2019, after both. A single bend fitted to the whole curve falls at 2016, but for organic chemistry papers alone it fits about as well at 2012. Citations divide in a similar way. Since 2016, about one in five bicyclopentane papers cites the two strain-release papers. Counting the lab’s decarboxylative-coupling and 1,2-bicyclopentane papers as well, 263 of 892 (29%) cite at least one lab paper that makes a bicyclopentane. Pfizer’s 2012 paper is cited by 255 (29%). Most, 59%, cite neither. The Science paper has been cited more often than the Pfizer paper in every year since 2016. The fairest summary is that Pfizer showed why chemists should want the ring, and strain-release amination gave them the first general way to install it, along with a name for the idea.

Other groups soon extended the chemistry. Paul Knochel’s group, with Novartis, made bicyclopentane mimics of internal alkynes and para-disubstituted benzenes from propellane (2017), and Masanobu Uchiyama’s group reported a radical multicomponent carboamination (2017). Edward Anderson’s group, with Pfizer’s Stepan, used a classical triethylborane-initiated radical addition to make highly functionalized 1-halo-3-substituted bicyclopentanes (2018). Patrick Walsh’s group added 2-azaallyl anions to make bicyclopentyl benzylamines (2018), and James Gleason’s group developed an aminoalkylation that gives 3-alkylbicyclopentan-1-amines directly (2019). Varinder Aggarwal’s group used 1,2-metallate rearrangements of boronate complexes (2020), and David MacMillan’s group reported a copper-mediated synthesis of drug-like bicyclopentanes (2020). Daniele Leonori’s group titled its nitrogen-radical method a “divergent strain-release amino-functionalization” of propellane (2020). Reviews have since recorded where the idea came from. Writing in Chemical Science, chemists at Janssen and two universities called 2016 “a watershed moment for reinvigorating interest in BCBs,” when “Baran and co-workers investigated the reaction of BCBs with amide nucleophiles” (Kelly et al., 2022). A 2023 review in Communications Chemistry describes the addition of amines to arylsulfonyl bicyclobutanes as “pioneered by Baran and co-workers” (Golfmann & Walker, 2023). The 2023 JACS Au review credits the lab’s phenyllithium protocol with improving “the yield, scalability, and purity” of propellane, and its turbo-amide method with “rendering the exploration of N-substituted BCPs in drug discovery far easier.” The 2020 Chemical Communications review quoted in the previous chapter goes furthest, crediting the lab with launching “the real renaissance of strain-release driven transformations” (Turkowska, Durka & Gryko, 2020).

The lab has returned to these rings several times. In 2021, again with Pfizer, it made 1,2-difunctionalized bicyclopentanes as long-sought mimics of ortho- and meta-substituted benzenes (PNAS 2021). A 2024 review calls this “the first investigation of 1,2-BCPs as an isosteric replacement for ortho-benzene” (Diepers & Walker, 2024). In 2025, with Benjamin Cravatt’s group, the lab used strain-release functionalization of 1-azabicyclobutanes to build enantiocontrolled azetidine libraries for chemical proteomics (J. Am. Chem. Soc. 2025). With Lara Malins, Pavel Mykhailiuk and their groups, it showed that dibromocarbene addition to bicyclobutanes gives substituted bicyclopentanes without using propellane at all (PNAS 2025). And a Ni-electrocatalytic method now assembles 1,1-diaryl cyclobutanes, azetidines and oxetanes from three components (Nature Chemistry 2026).

Graphical abstract: Strain-Release Amination
Strain-release amination (Science 2016): “spring-loaded” C–C and C–N bonds react directly with amines. Graphical abstract from Strain-Release Amination, Science 2016 · doi:10.1126/science.aad6252
07 The latest

Sulfonyl hydrazides, now from a catalogue

The newest reagents are also the simplest to use. Sulfonyl hydrazides are “stable and usually crystalline substances” that release an alkyl radical and an electron at the same time, so a coupling needs no external reductant, light or electricity.

Graphical abstract: Sulfonyl Hydrazides as a General Redox-Neutral Platform for Radical Cross-Coupling
Seven redox-neutral C–C couplings from one family of reagents (Science 2025): with olefins, alkyl halides, redox-active esters, aryl, alkenyl and alkynyl halides, and a trifluoromethylating reagent. Graphical abstract from Sulfonyl Hydrazides as a General Redox-Neutral Platform for Radical Cross-Coupling, Science 2025 · doi:10.1126/science.adu6406

The 2025 Science paper calls the reactions “homogeneous, water tolerant, dump-and-stir.” A follow-up in Angewandte built a toolbox of 14 fragments that medicinal chemists reach for most, from methyl and CD3 to cyclopropyl, oxetane, azetidine and bicyclopentyl, across more than 60 heteroaryl halides; the 2026 review notes that many of them are now commercially available.

Suppliers list sulfonyl hydrazides, alkyl sulfinates and TCNHPI redox-active esters for radical cross-coupling. Knight Chemicals sells a starter kit, KITT 1.0, with nine sulfonyl hydrazides (1 g each), ligands and a nickel precatalyst, and publishes a user guide. Links are listed for convenience; check each supplier for current availability.

08 Where it’s going

Beyond carbon–carbon

The hydrazide idea, losing N2 to make a radical, keeps finding new uses. In 2026 the lab reported a highly chemoselective route from alkyl hydrazines to alkyl–sulfur compounds (Nature Chemistry) and a nickel-catalysed, directed C(sp2)–H alkylation with alkyl sulfonyl hydrazides at low temperature (Nature Synthesis). The review on deleting redox lists C–N, C–O and C–F bonds and kilogram-scale reagent preparation as next goals.

The full story of radical cross-coupling

How these reagents fit into eighty years of cross-coupling, from polar bonds to deleting redox. See also the planning logic and reductive olefin coupling.

Cross-coupling deep dive →
Go deeper

Key reading

Reviews and essential papers, picked as a path into the field.

Start here

Alkyl Sulfinates: Radical Precursors Enabling Drug Discovery

Smith, J. M.; Dixon, J. A.; deGruyter, J. N. et al. · J. Med. Chem. 2019
Start here

Simplifying Radical Cross-Coupling by Deleting Redox

Neigenfind, P.; Kawamata, Y.; Baran, P. S. · ChemRxiv 2026 · Open access

Related papers

All lab papers tagged Reagents